Hi Mark,
CGS is a relatively small $390mn neuroscience technology company that makes money by providing cognitive testing services and software to pharmaceutical and biotech companies running clinical trials. It earns revenue through long-term contracts for study setup, test licensing, data management, analytics and ongoing support, as well as from healthcare providers using its cognitive assessment tools. Bells do cover the stock and have a $2.90 price target. Canaccord (Buy $3.15 PT) & Taylor Collison (Buy $3.51 PT) also have active coverage.
CGS does great work in the tough area of neurodegenerative diseases, particularly Alzheimer’s disease. It also supports clinical trials across other cognitive disorders, including Parkinson’s, schizophrenia, depression and brain injury, though Alzheimer’s remains its core area of activity.
There earnings numbers this week were solid with revenue coming in at $26.9mn and earnings per share (EPS) of $0.26 but we note that the stock has rallied strongly over the last 18-months. It trades on 22x consensus FY26 earnings.
- Revenue is forecast to grow by ~14% pa over the next 3 years, which looks very achievable, and is solid relative to valuation.
We like the company, though it often trading less than $500k a day. The risk/reward appeals to us ~$2, or 10% below Friday’s price.